STERIS Sees Fiscal 2026 Revenue Up 9%, Approves $1B Share Buyback
STE•STERIS reported fiscal 2026 revenue from continuing operations rose 9% to $5.9 billion with 7% constant-currency organic growth, and Q4 revenue climbed 7% to $1.6 billion with 5% organic growth. Adjusted EPS increased to $10.17, and the board approved a $1 billion share repurchase program.
1. Q4 and Full-Year Fiscal 2026 Results
Steris posted Q4 revenue of $1.6 billion, up 7% year-over-year with 5% organic growth, while fiscal 2026 revenue reached $5.9 billion, a 9% increase with 7% constant-currency organic growth. Adjusted EPS rose to $10.17 per diluted share, compared to $9.22 in the prior year.
2. Segment Performance
Healthcare segment revenue grew 7% to $1.14 billion in Q4, driven by 9% service revenue growth and 7% consumables increase. Applied Sterilization Technologies revenue climbed 6% to $289.2 million with a 10% service gain. Life Sciences revenue rose 9% to $162.9 million on 19% capital equipment growth.
3. Cash Flow and Share Repurchase
Steris generated $982.9 million in free cash flow for fiscal 2026, up from $787.2 million a year earlier. The board approved a new $1 billion share repurchase program to enhance shareholder returns.
4. Fiscal 2027 Outlook and Capital Investments
The company forecasts 7–8% revenue growth for fiscal 2027 with 6–7% organic growth and adjusted EPS of $11.10–11.30. Planned capital expenditures are $375 million, including a new sterility assurance plant in Ohio to consolidate U.S. production by late calendar 2026.
